<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986660</url>
  </required_header>
  <id_info>
    <org_study_id>SST0225-US-011-001</org_study_id>
    <nct_id>NCT01986660</nct_id>
  </id_info>
  <brief_title>Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Strategic Science &amp; Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Strategic Science &amp; Technologies, LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how Ibuprofen Cream (SST-0225) is absorbed and&#xD;
      eliminated by the body under defined maximum dosing conditions and to evaluate the safety&#xD;
      under these conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, Tmax, Trough Concentrations Days 2 to 8, AUC 0-24, Steady State, T1/2</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory change from baseline</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Berger Bowman Skin Assessment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibuprofen Cream (SST-0225)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen Cream (SST-0225)</intervention_name>
    <arm_group_label>Ibuprofen Cream (SST-0225)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
          -  Men, women, 18 to 55 years&#xD;
&#xD;
          -  Females must not be pregnant or plan to become pregnant&#xD;
&#xD;
          -  BMI 18 to 30 kg/m2&#xD;
&#xD;
          -  Past or non-smoker&#xD;
&#xD;
          -  High probability of compliance with completion of study&#xD;
&#xD;
          -  Healthy as determined by investigator based on medical history, physical exam,&#xD;
             clinical laboratory tests, vital sign measurements, ECGs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of disorder that could interfere with completion of study&#xD;
&#xD;
          -  Unstable medical condition&#xD;
&#xD;
          -  Surgical or medical condition that may interfere with absorption, distribution,&#xD;
             metabolism or excretion of test drug&#xD;
&#xD;
          -  Positive Hep B, Hep C and/or HIV test&#xD;
&#xD;
          -  Positive urine drug screen&#xD;
&#xD;
          -  Any history of skin disorders, including psoriasis, eczema, tattoos, significant&#xD;
             scarring, healing wounds, skin lesions on knees or elbows&#xD;
&#xD;
          -  Significant disease&#xD;
&#xD;
          -  Any clinically important deviation from normal limits in physical exam, vital sign&#xD;
             measurements, 12 lead ECG, clinical laboratory test&#xD;
&#xD;
          -  History of drug abuse with 1 year&#xD;
&#xD;
          -  History of alcoholism with 1 year&#xD;
&#xD;
          -  Use of prescription medications or ibuprofen within 30 days of Day 1, use of OTC&#xD;
             drugs, herbal supplements and vitamins within 14 days of Day 1.&#xD;
&#xD;
          -  Use of investigational drug within 30 day of Day 1&#xD;
&#xD;
          -  Acute disease state within 7 days of Day 1&#xD;
&#xD;
          -  Consumption of grapefruit or grapefruit containing products within 72 hours of Day 1&#xD;
&#xD;
          -  Tobacco use/caffeine use within 48 hours of Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SST Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

